The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
 
Takeshi Yamada
Research Funding - Taiho Pharmaceutical (Inst)
 
Kozo Kataoka
Honoraria - Lilly; Merck; Takeda
Research Funding - Sysmex
 
Keita Mori
Speakers' Bureau - Chugai Pharma; Lilly Japan
 
Toshihiro Kudo
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Naoto Takase
No Relationships to Disclose
 
Kazuma Ito
No Relationships to Disclose
 
Kei Kimura
No Relationships to Disclose
 
Jihyung Song
No Relationships to Disclose
 
Nobuhisa Matsuhashi
Honoraria - Amco; Asahi Kasei; Chugai Pharma; Covidien; Daiichi Sankyo; Gunze Medical; Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck KGaA; Miyarisan pharmaceutical; MSD; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation (Inst); EPS Holdings (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Shift Zero (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Toshimitsu Miyasaka
No Relationships to Disclose
 
Jesse Yu Tajima
No Relationships to Disclose
 
Naohito Beppu
No Relationships to Disclose
 
Hirotsugu Eda
No Relationships to Disclose
 
Yuka Oi
Employment - Sysmex
Stock and Other Ownership Interests - Sysmex
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Masataka Ikeda
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; Olympus; Ono Pharmaceutical; Pfizer; Shionogi; Sysmex; Terumo; Tsumura & Co.; Yakult Pharmaceutical
Research Funding - Daiichi Sankyo